Alimta Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Pemetrexed;   Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Cisplatin Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials